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28 Oral Presentationsaplasia. Cytogenetics revealed trisomy 8 mosaicism, present on
a BM specimen obtained pre-GTx (Blood 2007; 109:503). Our
2nd patient enrolled in January 2007. He received 5  106
CD341 cells/kg that showed 40–200U of ADA activity after trans-
duction (normal range 58–128). Over 6 months, this patient showed
a slow increase in ALC (up to 750/mcL) and lymphocyte function.
PBMC ADA activity has been up to 50U. The dAXP level has de-
creased to below 10%, levels typically seen after allogeneic BM
transplant. A 3rd patient was treated in May 2007 and received 2
 106 CD341 cells/kg with ADA activity of 7–87U. Over three
months, lymphocyte function has increased over pretreatment level.
PBMC ADA activity has been up to 24U and the dAXP levels have
decreased to less than 10%. Both patients have been off PEG-ADA
since 2 weeks pre-GTx and had mild post-GTx courses, with no
documented infection, and no need for blood products. AST and
ALT rose to 200 U/L, and then resolved, an effect attributed to
PEG-ADA withdrawal or busulfan administration. Without mye-
loid growth factors, times to neutrophil count above 500/mcL
were 36 and 45 days. These data are consistent with the positive re-
sults of GTx for ADA-SCID obtained in Milan and London and di-
rectly show that PEG-ADA withdrawal and reduced conditioning
improve the outcome of GTx for ADA-SCID. Longer follow-up
should allow us to study engraftment of cells containing vector-spe-
cific sequences and to conclude if either vector contributes more to
recovery of lymphoid immunity.69
SIROLIMUS (SRL)-BASED GVHD PROPHYLAXIS AFTER TBI/TT/CY ALLO-
GENEIC HSCT IN PEDIATRIC PATIENTS WITH HR ALL: RESULTS OF
A MULTI-INSTITUTIONAL PILOT STUDY
Pulsipher, M.A.1, Wall, D.2, Goyal, R.3, Grupp, S.4, Bunin, N.4. 1Uni-
versity of Utah/Primary Children’s Medical Center, Salt Lake City, UT;
2Methodist Children’s Hospital, San Antonio, TX; 3Children’s Hospital
of Pittsburgh, Pittsburgh, PA; 4Children’s Hospital of Philadelphia, Phil-
adelphia, PA.
Relapse and NRM after allogeneic HSCT remain significant bar-
riers to success in treating very high-risk ALL. Sirolimus (SRL) has
been shown to have cytotoxic activity against human ALL at serum
levels used for immune suppression. We hypothesized that the ad-
dition of SRL to a tacrolimus (TAC)/methotrexate (MTX) GVHD
prophylaxis regimen would decrease relapse after HSCT for ALL.
This multi-institutional pilot trial included a preparative regimen
of fractionated TBI (1200 cGy), thiotepa (5 mg/kg/d 2) and cyclo-
phosphamide (60 mg/kg 2). Pts received IV TAC (start d-2, target
5–10 ng/mL), PO SRL (start d0, target 3–12 ng/mL), and IV MTX
(5 mg/m2, d1 1,13, and16 plus d1 11 for UD BM/PBSC). TAC
was tapered between d 1 42–96 for MSD and d 1 100–180 for
others. SRL was tapered over 4 wks starting 6 m after transplant.
This report includes 50 pediatric pts (med age 9 (1–21)) with
a med f/u of 17 m (5–50). Immunophenotypes included 38 B-line-
age and 12 T-lineage. Risk groups included 12 pts in high risk
(HR) CR1, 5 in HR isolated extramedullary (IEM) relapse, 8 in
very early relapsing (VER,\18 m) CR2, 6 in early relapsing (ER,
18–36 m) CR2, 10 with late relapsing (LR, $36 m) CR2, and 9 in
CR3. Stem cell sources included 22 MSD-BM, 25 UCB, and 3 UD.
Results: 2 yr EFS for the entire cohort was 72% (SE 8.1) and did
not differ by stem cell source. 2 yr EFS by risk groups is outlined in
the table below, showing better than anticipated survival in all sub-
groups. Within the HR CR2 subgroups (BM relapse\36 m from
diagnosis), T-lineage VER CR2 pts had worse 2 yr EFS compared
to B-lineage VER CR2 and B- and T-lineage ER CR2 pts (2 yr EFS
20% vs. 64%, p5 0.057). One recipient of CB failed to engraft and
a second relapsed prior to engraftment. All remaining pts engrafted
at a median of 21 (13–31), 28 (16–62), and 20 (17–21) days for MSD,
CB, and UD, respectively. aGVHD grade II-IV and III-IV oc-
curred in 40 and 21% of patients, while cGVHD occurred in
30%. NRM occurred in 5 patients (10%: 4 CB, 1 MSD). Significant
toxicities included VOD (5 pts, reversible in 3, part of fatal MSOF
in 2 in the context of bacterial (1) and viral (1) sepsis), non-fatal
HUS (2 pts), and non-fatal IPS (1 pt). In summary, SRL-based
GVHD prophylaxis after TBI/TT/Cy allogeneic HSCT results
in high rates of engraftment, low NRM, and improved 2 yr EFSin every risk group except T-lineage VER in CR2. A phase 3 trial
in the COG for ALL patients in CR2 comparing TAC/MTX
with TAC/MTX/SRL after TBI/TT/Cy allogeneic HSCT is on-
going.2 yr EFS by Risk Group
ALL Risk ALL HR ALLVER ALL ER ALL LR ALL IEMGroup CR1 CR2 CR2 CR2 ALL CR3 CR22 yr EFS (±SE) 92% (±8) 38% (±17) 60% (±22) 90% (±10) 65% (±17) 100%70
IMPROVED OUTCOME FOR TRANSPLANTATION OF PEDIATRIC PA-
TIENTSWITHNON-MALIGNANT DISORDERSWITH UNWASHED PLASMA
DEPLETED CORD BLOOD (PD CB)
Rosenthal, J.1, Jaing, T.-H.2, Chan, L.L.3, Eames, G.4, Graham, M.5,
Tan, A.M.6, Lin, H.P.7, Nademanee, A.1, Karanes, C.1, Wang, B.8,
Chow, T.8, Tan, P.9, Gjertson, D.10, Petz, L.8, Chow, R.8,11,
Forman, S.1. 1City of Hope National Medical Center, Duarte, CA;
2Chang GungUniversity & Children’s Hospital, Linkou, Taiwan; 3Uni-
versity ofMalayaMedical Center, Kuala Lumpur,Malaysia; 4Cook Chil-
dren’s Hospital, FortWorth, TX; 5University of ArizonaMedical Center,
Tucson, AZ; 6KK Women & Children’s Hospital, Singapore; 7Subang
Jaya Medical Center, Malaysia; 8StemCyte International Cord Blood
Center, Arcadia, CA; 9Mount Elizabeth Hospital, Singapore; 10UCLA
School of Public Health, Los Angeles, CA; 11StemCyte Taiwan National
Medical Center, Linkou, Taiwan.
CB is an attractive source for unrelated transplantation of benign
indications because of the potentially better availability for minori-
ties. Since most patients are children, cell dosage is less of a limita-
tion; however, cell dose is still important. We have consistently
employed 3 strategies to maximize cell dose - plasma depletion pro-
cessing without red blood cell reduction, no post-thaw wash (NW),
and the use of double cords (2X) when necessary. A retrospective
CIBMTR-audited analysis was performed on all 87 pediatric
(\50 kg) patients with non-malignant disorders transplanted with
98 PD CB products (15 double cords) at 21 US and 16 international
institutions. Weight was used instead of age to emphasize impor-
tance of cell dose. The disease breakdowns were: 40 thalassemias,
12 congenital immunodeficiency syndromes, 9 aplastic anemia, 5
Hurler syndrome, 4 osteopetrosis, 2 chronic granulomatous dis-
ease, 2 familial hemophagocytosis, 2 Fanconi anemia, 2 inherited
metabolic disorders, and 9 for other disorders. Transplant charac-
teristics: median age 4 years (range 0.1–27); median weight 16 kg
(range 4–49); male 54%; HLA ABDR matches: 18–6/6; 32–5/6;
30–4/6; 6–3/6, 1–2/6; median pre-freeze TNC dose 9.8  107/kg;
median post-thaw TNC dose as reported by TC 6.7  107/kg; me-
dian pre-freeze CD341 dose 3.5  105/kg; transplants outside of
U.S.- 54 (62%); non-myeloablative - 13 (15%); 34% post-thaw
washed (W) and 66% infused without post-thaw wash (NW) of
those with known post-thaw status. Median follow-up time was
220 days (range 8–1,448 days). With no unevaluable cases, cumula-
tive incidence was used to estimate engraftment, acute and chronic
graft-versus-host disease (aGvHD and cGvHD), and Kaplan-Meier
estimates were used for all other outcome. As shown below, forego-
ing post-thaw wash improved engraftment, TRM and survival, and
significantly reduced extensive cGvHD. This series is unusual in its
cell dose, high even for pediatric patients, and shows that unrelated
PD CB transplantation can be performed safely and effectively, with
outstanding neutrophil (92 6 9%) and platelet engraftment (85 6
9%), extensive cGvHD (3 6 3%), overall (90 6 4%) and disease-
free survival (78 6 6%) rates achieved when post-thaw wash is not
employed, even in a diverse population of pediatric patients with
non-malignant disorders.
Oral Presentations 29Outcome Summary
ANC500Table. GVH
HCT recipien
Groups
Transplant
type
GVHD
score
± SD
T-R5T ce
or #4 vs.& median
timeD scores
ts
#1 (T
spleno
(d0
(no NK
2.8 ±
ll replet
#1 or #Plt 20 K %
median timbetween d
-R)
cytes
)
cells)
s
(n
0.4
e HCT, T
2 5 p\Grade II-IV
aGvHDay125 a
#2 (T-D)
plenocyt
(d 1 4)
o NK ce
3.0 ± 0.7
-D5T
0.001, stExtensive
cGvHDnd145
#3
es
lls)
sple
(d0
(d
0.
cell dep
udents u1-Yr TRMin 4 diff
(T-R)
nocytes
) 1 NK
1 4)
5 ± 0.4
lete HC
npaired1-Yr OSerent coh
#4 (
spleno
(d 1
NK
0.7 ±
T. Gro
T-test1-Yr DFSAll Patients
(n 5 87)87 ± 7%
20 days77 ± 7%
50 days34 ± 6% 12 ± 4% 19 ± 4% 81 ± 4% 68 ± 6%NW (n 5 57) 92 ± 9%
19 days85 ± 9%
46 days37 ± 8% 3 ± 3% 10 ± 4% 90 ± 4% 78 ± 6%W (n 5 30) 80 ± 11%
22 days65 ± 11%
58 days31 ± 8% 23 ± 8% 35 ± 9% 65 ± 9% 53 ± 10%Cox RR &
P-value (W
Reference)1.76 0.03 1.67 0.07 1.20 0.65 0.11 0.04 0.27 0.02 0.27 0.02
(death)0.54 0.13
(death or
relapse)SOLID TUMORS71
ADOPTIVE INFUSION OF DONOR NK CELLS REDUCES GVHD IN RECIPI-
ENTS OF T-CELL DEPLETED AND T-CELL REPLETE ALLOGENEIC MHC-
MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION
Lundqvist, A., Childs, R. NHLBI, NIH, Bethesda, MD.
Retrospective data suggest that alloreactive NK cell-mediated re-
duction in GVHD and disease relapse may be limited to patients
with AML undergoing T-cell depleted KIR ligand-mismatched al-
logeneic hematopoietic cell transplantation (HCT). Whether NK
cells can mediate similar beneficial effects following MHC-
matched, T-cell replete allogeneic HCT is currently unknown.
We investigated if an infusion of purified donor NK cells would re-
duce GVHD and simultaneously mediate anti-tumor effects in
a murine solid tumor model of MHC-matched allogeneic HCT.
Ten days following intravenous injection of 105 RENCA tumor
cells, BALB/c recipient mice were irradiated (950 cGy) and trans-
planted with 8  106 bone marrow cells from MHC-matched
B10.d2 donors. Recipients of a T-cell replete HCT additionally re-
ceived 15 106 splenocytes from MHC-matched B10.d2 donors on
day 0 whereas recipients of a T-cell depleted HCT received no sple-
nocytes on day 0 with or without a delayed infusion of donor lym-
phocytes (15  106 splenocytes) on day 14. All mice in groups
receiving splenocytes (day 0 or day 14) developed GVHD (weight
loss, alopecia and hunched posture) by day130 and died before day
160. In contrast, 60% of mice receiving splenocytes and purified
donor NK cells (0.5–5  106) on day 0 or day 14 remained free
of skin GVHD and had significantly lower GVHD scores (see Ta-
ble). Moreover, 40% of transplant recipients receiving splenocytes
and NK cells on either day 0 or day 14 survived $60 days post
transplant. To further characterize the NK cell subset responsible
for prolonging GVHD-free survival, donor NK cells were sorted
into BALB/c non-alloreactive Ly49 ligand-matched (Ly49G2)
and BALB/c alloreactive Ly49 ligand-mismatched (Ly49C) NK
cells. Recipients of Ly49C1 NK cells (given day 15) had signifi-
cantly less GVHD and prolonged survival (p\ 0.01) compared to
HCT recipients receiving Ly49G21 NK cells. No difference inorts of
T-D)
cytes
4) 1
(d0)
0.2
ups #3
.GVHD-free survival was observed between transplant recipients
of Ly49G21NK cells and controls not receiving NK cells. Pulmo-
nary tumor burden was significantly (p\0.01) lower in recipients of
Ly49C1 or Ly49G21 NK cells compared to mice not receiving
NK cells. These data provide in vivo evidence that a single infusion
of alloreactive donor NK cells can prolong survival by both reduc-
ing GVHD and mediating anti-tumor effects following MHC-
matched T-cell replete allogeneic HCT.STEM CELL BIOLOGY72
RECIPIENT BASED STRATEGIES FOR IMPROVED TRANSPLANT EFFI-
CIENCY: CD26 INHIBITOR TREATED AND CD26-/- RECIPIENT MICE EX-
HIBIT INCREASED SHORT-TERM HOMING AND LONG-TERM
ENGRAFTMENT OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
Paganessi, L.A., Gregory, S.A., Fung, H.C., Christopherson, K.W. Rush
University Medical Center, Chicago, IL.
Introduction: Through the use of CD26 inhibitors and CD26
deficient mice (CD26-/-), we have previously generated data sug-
gesting that suppression of CD26/DPPIV activity on the transplant
donor cell population could potentially be utilized clinically as
a method of increasing transplant efficiency. However, the clinical
importance of the transplant recipient should not to be overlooked.
We therefore investigated whether inhibition or loss of CD26 activ-
ity in the recipient would have an effect on hematopoietic stem cell
transplantation utilizing an in vivo congenic mouse model of trans-
plantation. Methods: The short-term homing and long-term en-
graftment of BoyJ donor cells (expressing CD45.11) into lethally
irradiated control C57BL/6, CD26 inhibitor (Diprotin A) treated
C57BL/6, or CD26-/- mice (expressing CD45.21) was monitored
by flow cytometric analysis of the bone marrow and peripheral
blood at 24 hours and 6 months post-transplant. Results:
Twenty-four hours post-transplant of 20  106 BoyJ mononuclear
cells, we observed 8.85 6 0.58%, 10.69 6 1.01%, and 12.45 6
1.33% donor derived Sca-11lin- cells in the bone marrow of recip-
ient mice for control, Diprotin A treated, and CD26-/- recipient
mice respectively. As compared to control mice, this represents
a 20.8% increase (p 5 0.01) with CD26 inhibitor treatment and
a 40.7% increase (p# 0.05) resulting from the use of a CD26-/- re-
cipient in short-term homing (N 5 5 mice per group). Six months
post-transplant of 1  105 BoyJ mononuclear cells, we observed
39.906 4.38%, 70.226 3.72%, and 92.51 6 1.04% donor contri-
bution to hematopoiesis in the peripheral blood of control, Dipro-
tin A treated, and CD26-/- recipient mice respectively. This
represents a 76.0% increase (p # 0.01) with CD26 inhibitor treat-
ment and a 131.9% increase (p# 0.01) as a result of the CD26-/- re-
cipient in long-term engraftment as compared to control recipient
mice (N5 14 mice per group). Conclusions: These results provide
pre-clinical evidence of the importance of CD26 expression within
the transplant recipient with regard to regulating hematopoietic
stem cell homing and engraftment. Our results also support the po-
tential use of CD26 inhibitors to treat transplant patients during he-
matopoietic stem cell transplantation as a method of improving
transplant efficiency.
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HUMAN HEMATOPOIETIC PROGENITORS WITH SLOW DIVISIONAL KI-
NETICS RECONSTITUTE T CELLS IN THYMUS, B CELLS IN LYMPH NODES
AND MYELOID CELLS IN MARROW OF NOD/SCID MOUSE MODEL AND
REPRESENT THE MOST PRIMITIVE FRACTION
Schubert, M.1, Zoeller, M.2, Ho, A.D.1. 1University of Heidelberg, Hei-
delberg, Germany; 2German Cancer Research Center, Heidelberg, Ger-
many.
We have demonstrated that CD341 cells with slow division ki-
netics are associated with self renewal and increased frequency of
LTC-IC and myeloid-lymphoid initiating cells (ML-IC) in vitro.
The present study showed that only the slow dividing fraction
(SDF) of human CD341 cells, but not the fast dividing fraction
(FDF), is able to engraft the thymus and lymph nodes of NOD/
SCID mice.
